证券代码：688321 证券简称：微芯生物 公告编号：2025-042 一、药品的基本情况 西达本胺是公司独家发现的全新机制新分子实体药物，是全球首个亚型选择 性组蛋白去乙酰化酶（HDAC）抑制剂，属于表观遗传调控剂类药物。西达本胺 是国家 863 及"重大新药创制"专项成果。 深圳微芯生物科技股份有限公司 自愿披露关于西达本胺一线治疗弥漫大 B 细胞淋巴瘤的 III 期临床试验获得顶线分析数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳微芯生物科技股份有限公司（以下简称"公司"）自主研发的西达本胺 针对一线治疗弥漫大 B 细胞淋巴瘤（DLBCL）关键性 III 期临床试验（DEB 研 究）已于近日获得最终结果的顶线分析数据，试验组无事件生存期（EFS）显著 优于对照组，达成研究主要终点。现将相关情况公告如下： 2024 年 4 月，基于 DEB 研究期中分析综合数据结果，西达本胺联合 R-CHOP 用于 MYC 和 BCL2 表达阳性的既往未经治疗的 DLBCL 适应症获得国家药品监 督管理局附条件批准。 ...

微芯生物公告，公司自主研发的西达本胺针对一线治疗弥漫大B细胞淋巴瘤(DLBCL)关键性III期临床试 验(DEB研究)已于近日获得最终结果的顶线分析数据，试验组无事件生存期(EFS)显著优于对照组，达 成研究主要终点。微芯生物表示，西达本胺联合R-CHOP是全球首个在III期临床中完全缓解(CR)率显著 优于R-CHOP的一线DLBCL治疗方案。此次顶线分析中，试验组无事件生存期(EFS)较对照组展现具统 计学显著意义的差异，进一步验证了西达本胺联合方案可为初治MYC和BCL2双表达DLBCL患者带来显 著且可持续的疗效，且安全性良好。公司正在准备该适应症常规批准的申报。同时，该研究最终结果的 全面分析也将于后续学术会议或期刊中呈现。 ...

New Stock Offerings - 济川药业 (600566) has a tender offer period from June 18, 2025, to July 17, 2025[1] - *ST亚振 (603389) has a tender offer period from June 10, 2025, to July 9, 2025[1] - 中程退 (300208) has 7 trading days remaining until the last trading day[1] Delisting Notices - 退市锦港 (600190) has 7 trading days remaining until the last trading day[1] - 恒立退 (000622) has 4 trading days remaining until the last trading day[1] - 退市九有 (600462) has 3 trading days remaining until the last trading day[1] Abnormal Fluctuations - 北方长龙 (301357) reported severe abnormal fluctuations[1] - 浙江东日 (600113) reported abnormal fluctuations with an announcement time of June 28, 2025[1] - 诺德股份 (600110) reported abnormal fluctuations with an announcement time of June 27, 2025[1]

沪深两市全天主力资金净流入154.50亿元，其中，科创板主力资金净流入4.56亿元，主力资金净流入的 有248只股，主力资金净流出的有337只股。 证券时报·数据宝统计显示，今日科创板个股上涨的有478只，涨停的有美迪西等1只，下跌的有107只。 其中，今日新上市的C屹唐，收盘涨幅为174.56%。 资金流向方面，今日主力资金净流入的科创板股共有248只，其中，3只个股主力资金净流入超亿元，C 屹唐主力资金净流入9.18亿元，净流入资金居首；中芯国际、澜起科技紧随其后，全天净流入资金分别 为1.57亿元、1.37亿元。主力资金净流出的有337只，净流出资金最多的是瑞联新材，该股今日下跌 9.93%，全天主力资金净流出1.73亿元，其次是微芯生物、神州细胞，主力资金净流出分别为1.62亿 元、1.31亿元。 今日上市的新股C屹唐收盘上涨174.56%，全天换手率为77.43%，主力资金净流入9.18亿元。 从主力资金连续性进行观察，共有45只个股主力资金连续3个交易日以上持续净流入，连续流入天数最 多的是正帆科技，该股已连续17个交易日净流入；连续净流入天数较多的还有百利天恒、威高骨科等， 主力资金分别连续流入 ...

New Stock Listings - Yitang Co., Ltd. (688729) listed at an issue price of 8.45 on July 8, 2025[1] - Jichuan Pharmaceutical (600566) has a tender offer period from June 18 to July 17, 2025[1] - ST Yazhen (603389) has a tender offer period from June 10 to July 9, 2025[1] Delisting and Trading Reminders - Tui Shi Jin Gang (600190) has 8 trading days remaining until the last trading day[1] - Hengli Tui (000622) has 5 trading days remaining until the last trading day[1] - Tui Shi Jiu You (600462) has 4 trading days remaining until the last trading day[1] Market Volatility - North China Long Dragon (301357) reported severe abnormal fluctuations[1] - Multiple stocks including ST Zhengping (603843) and Hunan Tianyan (600698) have reported abnormal fluctuations[3]

New Stock Issuance - Huadian New Energy (证券代码: 730930) issued shares at a price of 3.18 on July 7, 2025[1] - Jichuan Pharmaceutical (证券代码: 600566) has a tender offer period from June 18 to July 17, 2025[1] - ST Yazhen (证券代码: 603389) has a tender offer period from June 10 to July 9, 2025[1] Trading Alerts - The last trading day for TSM Jinguang (证券代码: 600190) is in 9 trading days[1] - The last trading day for TSM Jinyou (证券代码: 600462) is in 5 trading days[1] - The last trading day for TSM Gongzhi (证券代码: 000584) is in 3 trading days[1] Abnormal Fluctuations - Northern Long (证券代码: 301357) is experiencing severe abnormal fluctuations[1] - ST Dongjing (证券代码: 002199) reported abnormal fluctuations[3] - ST Yunchuang (证券代码: 835305) reported abnormal fluctuations on July 4, 2025[3]

证券研究报告 医药生物 行业定期报告 hyzqdatemark 2025 年 07 月 06 日 刘闯 SAC：S1350524030002 liuchuang@huayuanstock.com 板块表现： "HDAC+IO"潜力值得期待，重视微芯生物 投资评级： 看好（维持） ——医药行业周报（25/6/30-25/7/4） 投资要点： 请务必仔细阅读正文之后的评级说明和重要声明 证券分析师 联系人 本周医药市场表现分析：6 月 30 日至 7 月 4 日，医药指数上涨 3.64%，相对沪深 300 指数超 额收益为 2.10%。本周，涨幅靠前的主要为创新药标的如塞力医疗、广生堂、神州细胞、热 景生物，核心因素为临床数据更新催化，我们认为 6 月下旬以来创新药板块的调整已到位， 继续看好创新药，关注下半年有 BD 强催化的核心标的。建议关注：1）创新药作为较为确定 的产业趋势，建议关注：A 股）热景生物、华纳药厂、微芯生物、悦康药业、前沿生物、福元 医药、信立泰、一品红、科兴制药、泽璟制药、科伦药业、恒瑞医药；港股）三生制药、中 国生物制药、科伦博泰、康方生物、信达生物、翰森制药；2）25 年业绩或逐季度边 ...

Core Viewpoint - Shenzhen Micu Biotechnology Co., Ltd. experienced a significant stock price fluctuation, with a cumulative closing price increase of 30% over three consecutive trading days from July 1 to July 3, 2025, which is classified as abnormal trading activity according to relevant regulations [2][4]. Group 1: Stock Trading Abnormality - The company's stock price increased by a cumulative 30% over three trading days, indicating abnormal trading activity [2][4]. - The company has conducted a self-examination and confirmed that there are no undisclosed significant information affecting the stock price [5][6]. Group 2: Company Operations and Information Disclosure - The company's production and operational activities are normal, with no significant changes in market conditions, industry policies, or production costs [5]. - There are no undisclosed major events such as mergers, acquisitions, or restructuring that could impact the company's stock price [6][7]. - The company has not identified any media reports or market rumors that could have significantly influenced its stock price [7]. Group 3: Board of Directors' Statement - The Board of Directors confirms that there are no undisclosed matters that should be reported according to the relevant regulations [9]. - The company emphasizes the importance of timely and accurate information disclosure to assist investors in making informed decisions [10].

Core Viewpoint - Shenzhen Micu Biotechnology Co., Ltd. experienced a significant stock price fluctuation, with a cumulative increase of 30% over three consecutive trading days from July 1 to July 3, 2025, which is classified as abnormal trading activity according to relevant regulations [1][2]. Group 1: Stock Trading Abnormalities - The company's stock price increased by 30% over three trading days, indicating abnormal trading activity as per the Shanghai Stock Exchange rules [1]. - The company conducted a self-examination and confirmed that there are no undisclosed significant information affecting the stock price, including mergers, debt restructuring, or asset transfers [2]. Group 2: Company Operations and Market Conditions - The company reported that its production and operational activities are normal, with no significant changes in market conditions or industry policies [2]. - There have been no major fluctuations in production costs or sales, and the internal operational order remains stable [2]. Group 3: Board of Directors' Statement - The Board of Directors confirmed that there are no undisclosed matters that should be reported according to the Shanghai Stock Exchange rules, and they have not been made aware of any significant information that could impact the stock price [2].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 深圳微芯生物科技股份有限公司（以下简称"公司"）股票交易价格连 续三个交易日（2025 年 7 月 1 日、2025 年 7 月 2 日、2025 年 7 月 3 日）内收 盘价格涨幅偏离值累计达到 30% 。根据《上海证券交易所交易规则》《上海证 券交易所科创板股票异常交易实时监控细则》的有关规定，属于股票交易异常 波动的情形。 证券代码：688321 证券简称：微芯生物 公告编号：2025-041 深圳微芯生物科技股份有限公司 股票交易异常波动公告 公司股票价格短期波动幅度较大，敬请广大投资者注意二级市场交易风 险，理性决策，审慎投资。 一、股票交易异常波动的具体情况 经公司自查，并向公司控股股东及实控人 XIANPING LU 博士核实，截 至本公告披露日，公司及控股股东、实际控制人不存在应披露而未披露的重大信 息。 所交易规则》《上海证券交易所科创板股票异常交易实时监控细则》的有关规定， 属于股票交易异常波动的情形。 二、公司关注并核实的相关情况 针对 ...